AOD 9604 vs semaglutide has an uneven answer.
For demonstrated weight loss in people, semaglutide has the stronger evidence. We can say that plainly without picking a medicine for you.
Better for which job?
Appetite, body weight and muscle fuel use are different questions. Putting three compounds in the same search result doesn’t make their evidence equal. We follow the result that answers the question you actually have.
Use
the human weight findings
Semaglutide demonstrated weight loss in a human trial. AOD-9604 failed to show a clear weight-loss advantage in its main obesity trial, and that development stopped. The AOD-9604 human report describes the trial program behind that history.
These were separate studies. We can judge which has stronger evidence without inventing a direct contest between the two. There is no head-to-head difference to calculate here.
Store
each proposed effect in its own place
Semaglutide works on appetite. AOD-9604 was developed to affect fat metabolism. MOTS-c has cell and mouse findings about fuel handling. Different jobs can all sound useful, but that doesn’t give them the same evidence for helping people.
MOTS-c’s unanswered treatment question isn’t an advantage over AOD-9604’s disappointing result. Unknown doesn’t mean better. The MOTS-c page explains what still needs a human test.
Respond
to safety separately
Semaglutide’s documented unwanted effects include digestive and gallbladder problems. AOD-9604’s oral obesity trials reported tolerability similar to the dummy treatment, over no more than 24 weeks. That doesn’t establish injection safety. MOTS-c lacks an established human safety profile.
Those differences matter. We can’t call the less-studied compound “gentler” just because fewer problems have been recorded. There may simply be less opportunity to see them.
A pair needs evidence for the pair.
The studies linked here don’t test AOD-9604 and semaglutide together. They establish no added benefit or safety profile for that combination. Adding MOTS-c doesn’t solve the problem. Two proposed jobs might suggest an experiment; they don’t tell us that combining treatments helps.
Keep the verdict useful.
Our judgement concerns demonstrated human weight loss: semaglutide has the stronger record. It isn’t a ranking for every possible metabolic problem, and it isn’t a treatment recommendation. Your health history and the exact medicine would still need a clinician’s attention.
There are FDA-approved semaglutide products. AOD-9604 and MOTS-c have no FDA approval. Compounded medicines, prepared by a pharmacist or doctor, have no FDA approval either. A prescription route answers an access question; it doesn’t prove benefit.
The FAQ unpicks the questions that tend to get bundled together.